Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.
Cencora, Inc. (NYSE: COR) generates frequent news and disclosures that reflect its role as a large pharmaceutical solutions and distribution company. Its press releases and earnings announcements highlight how the organization partners with pharmaceutical innovators, supports care providers with secure and reliable delivery of pharmaceuticals and healthcare products, and advances its pharmaceutical-centric strategy across U.S. and international markets.
Investors and healthcare professionals following Cencora news can expect regular updates on quarterly and annual financial results, including detailed discussions of revenue trends, gross profit, operating income, and adjusted non-GAAP metrics for its U.S. Healthcare Solutions and International Healthcare Solutions segments. The company also issues announcements about earnings release dates and conference calls, providing access information for live webcasts and replays.
Cencora’s news flow often covers strategic transactions and investments, such as the acquisition of Retina Consultants of America (RCA) and the agreement to acquire additional equity interests in OneOncology, a physician-led oncology platform. These updates explain how such moves are intended to strengthen specialty solutions, enhance research and clinical trial capabilities, and support community-based care. Other releases describe investments in the distribution network, including plans for a second national distribution center and expanded cold chain capacity.
Corporate governance and board developments are another recurring theme, with announcements about board appointments, leadership transitions, and committee actions. In addition, Cencora issues news on specialty data and analytics offerings through IntrinsiQ Specialty Solutions, including expanded oncology biomarker data and insights for manufacturers and physicians.
By monitoring Cencora’s news page, readers can track financial performance, capital allocation decisions, specialty care initiatives, board-level changes, and data-driven solutions that shape the company’s role in the healthcare and pharmaceutical distribution landscape.
Cencora (NYSE: COR) closed a $3.0 billion underwritten offering of senior notes across five tranches: $500M 3.950% due 2029, $500M 4.250% due 2030, $500M 4.600% due 2033, $1.0B 4.900% due 2036 and $500M 5.650% due 2056.
According to the company, net proceeds will repay amounts outstanding under its 364-Day Term Credit Agreement used to fund the OneOncology acquisition, with any remaining proceeds for general corporate purposes. Joint book‑running managers were Citigroup, J.P. Morgan, BofA and Wells Fargo.
Cencora (NYSE: COR) priced a $3.0 billion underwritten senior note offering across five tranches due 2029, 2030, 2033, 2036 and 2056 with coupon rates from 3.950% to 5.650%.
Proceeds are intended to repay amounts under Cencora’s 364-Day Term Credit Agreement used to fund the OneOncology acquisition, with closing expected February 13, 2026. The offering is made from an effective shelf registration filed November 26, 2024.
Cencora (NYSE: COR) reported fiscal 2026 first quarter results for the period ended December 31, 2025: revenue $85.9B (+5.5% YoY), GAAP diluted EPS $2.87, and adjusted diluted EPS $4.08 (+9.4% YoY). The company completed the acquisition of OneOncology and raised adjusted operating income guidance to +11.5% to +13.5% while reaffirming adjusted diluted EPS guidance of $17.45–$17.75 for fiscal 2026. A quarterly dividend of $0.60 per share was declared, payable March 2, 2026.
Cencora (NYSE: COR) elected Ellen Cooper to its Board of Directors, effective January 20, 2026. Ms. Cooper is chairman, president and CEO of Lincoln Financial and became CEO in May 2022. Her background includes roles as Executive VP and Chief Investment Officer at Lincoln, Managing Director and Global Head of Insurance Strategy at Goldman Sachs Asset Management, Chief Risk Officer for AEGON Americas, and Principal at Ernst & Young.
She holds a BBA from Temple University and professional credentials including Fellow of the Society of Actuaries, Chartered Enterprise Risk Analyst, and Chartered Financial Analyst.
Cencora (NYSE: COR) will release its First Quarter Fiscal 2026 results on Wednesday, February 4, 2026 before the NYSE opens and will host a conference call at 8:30 a.m. ET the same day.
Management participants: Robert P. Mauch, President & Chief Executive Officer, and James F. Cleary, Executive Vice President & Chief Financial Officer. The live webcast and replay will be available at investor.cencora.com. Webcast replay will be posted about one hour after the call and will remain available for one year; telephonic replay will be available for seven days.
Cencora reports having 51,000+ employees worldwide and more than $300 billion in annual revenue; investors should check the investor website for updates and access details.
Cencora (NYSE: COR) agreed to acquire the remaining majority equity interests in OneOncology, valuing the platform at $7.4 billion enterprise and approximately $6.0 billion equity. Cencora will pay ~$3.6 billion to purchase shares and retire ~$1.3 billion of OneOncology corporate debt, for total cash consideration of ~$5.0 billion. The deal is expected to close by the end of Cencora's fiscal 2026 Q2, subject to customary conditions and regulatory approvals.
The transaction will be debt-funded; Cencora says it will prioritize deleveraging and maintain investment-grade ratings. Management paused share repurchases and expects the deal to be approximately EPS-neutral (adjusted) in the first 12 months. Cencora raised long-term guidance ranges for adjusted operating income (7–10%) and adjusted diluted EPS (10–14%), and reiterated fiscal 2026 consolidated guidance.
Cencora (NYSE: COR) reported fourth-quarter fiscal 2025 revenue of $83.7B, up 5.9% year‑over‑year, and fiscal 2025 revenue of $321.3B, up 9.3%. Fourth‑quarter GAAP diluted EPS was $(1.75) while adjusted diluted EPS was $3.84 (+15.0%). Fiscal year GAAP diluted EPS was $7.96 and adjusted diluted EPS was $16.00 (+16.3%).
The company cites the January 2025 acquisition of Retina Consultants of America (RCA) as a key driver, recorded goodwill impairments related to PharmaLex, plans $1B of U.S. distribution investments through 2030, and raised long‑term guidance expectations. The board approved a 9% quarterly dividend increase to $0.60 per share, payable Dec 1, 2025.
IntrinsiQ Specialty Solutions (NASDAQ:COR) announced expanded data capabilities on October 16, 2025 to deliver oncology biomarker data and enhanced therapeutic insights across oncology, retina and other therapeutic areas. Key goals are to enable precision medicine, help physicians tailor cancer therapies, and give manufacturers a fuller view of real-world utilization and adoption.
The offering combines biomarker data with physician and clinical care insights to support targeted outreach, education, and improved patient outcomes while leveraging Cencora's distribution and integrated specialty solutions.
Cencora (NYSE: COR) will release Fourth Quarter Fiscal 2025 results on Wednesday, November 5, 2025 prior to NYSE open and will host a conference call at 8:30 a.m. ET the same day.
Management on the call: Robert P. Mauch (CEO) and James F. Cleary (CFO). The live webcast and replay will be available at investor.cencora.com. Teleconference access and replay phone numbers and access codes are provided for domestic and international callers.
Cencora (NYSE: COR) has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Durcan succeeds Steven H. Collis, who served as Chairman since 2016 and previously as CEO from 2011 to 2024.
Durcan brings significant experience as the former CEO of Micron Technology (2012-2017) and has served on Cencora's Board since 2015, becoming Lead Independent Director in 2023. He currently serves as a director of ASML Holding NV and on Rice University's Board of Trustees.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
